News & Updates

Show Multimedia Only

Stopping anti-TNF therapy risky in paediatric IBD

18 Jul 2026 by

Paediatric inflammatory bowel disease (IBD) patients who have achieved clinical remission on tumour necrosis factor inhibitor (anti-TNF) therapy are likely to flare if they stop treatment, researchers from the IBD Porto Group of ESPGHAN have found.

Stopping anti-TNF therapy risky in paediatric IBD

18 Jul 2026

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

17 Jul 2026 by

Nearly a third of glioblastoma patients treated with standard radiotherapy plus temozolomide (STUPP protocol) suffer early-onset radiation induced leukoencephalopathy (RIL), which is linked to early cognitive and functional decline, according to a study.

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

17 Jul 2026

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

17 Jul 2026 by

The investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib demonstrates its noninferiority to ocrelizumab in reducing the risk of disability progression in patients with primary progressive multiple sclerosis (PPMS) in the phase III FENtrepid study.

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

17 Jul 2026

Does MS relapse after stopping ponesimod?

17 Jul 2026 by

In a post hoc analysis of the OPTIMUM* long-term extension (OPTIMUM-LTE) study, discontinuation of ponesimod did not lead to a clinically meaningful disease reactivation or rebound effect in patients with relapsing multiple sclerosis (MS).

Does MS relapse after stopping ponesimod?

17 Jul 2026

Prenatal paracetamol exposure cleared of ASD, ADHD risk in offspring

17 Jul 2026

Children born to mothers who used paracetamol during pregnancy are unlikely to develop autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD), according to a study from Hong Kong.

Prenatal paracetamol exposure cleared of ASD, ADHD risk in offspring

17 Jul 2026

Nanoencapsulated sirolimus plus pegadricase helps patients with uncontrolled gout

16 Jul 2026

Treatment with nanoencapsulated sirolimus plus pegadricase yields higher response rates compared with placebo in patients with uncontrolled gout, according to the phase III DISSOLVE I and II studies.

Nanoencapsulated sirolimus plus pegadricase helps patients with uncontrolled gout

16 Jul 2026

Elobixibat bests prucalopride for functional constipation in head-to-head trial

16 Jul 2026 by

Elobixibat delivers superior symptom relief and quality-of-life improvements compared with prucalopride in the second-line treatment of patients with functional constipation, as shown in a head-to-head trial.

Elobixibat bests prucalopride for functional constipation in head-to-head trial

16 Jul 2026

Medication nonadherence more common in young vs older adults with SLE

16 Jul 2026

Self-reported medication nonadherence is greater among younger vs older adults with systemic lupus erythematosus (SLE), driven primarily by logistical barriers, reports a study.

Medication nonadherence more common in young vs older adults with SLE

16 Jul 2026

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

16 Jul 2026 by

In individuals receiving odevixibat for progressive familial intrahepatic cholestasis 2 (PFIC2), also known as bile salt export pump (BSEP) deficiency, reductions in serum bile acid (sBA) levels correlated with improvements in key liver function tests (LFTs), according to a post hoc subgroup analysis presented at ESPGHAN 2026.

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

16 Jul 2026

GLP-1 RAs confer cerebrovascular benefit in obstructive sleep apnoea

16 Jul 2026

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with obstructive sleep apnoea (OSA) may reduce the incidence of cerebrovascular events, minimize healthcare use, and lower all-cause mortality, according to a retrospective study.

GLP-1 RAs confer cerebrovascular benefit in obstructive sleep apnoea

16 Jul 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Stopping anti-TNF therapy risky in paediatric IBD

Stopping anti-TNF therapy risky in paediatric IBD

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

Does MS relapse after stopping ponesimod?

Does MS relapse after stopping ponesimod?

Prenatal paracetamol exposure cleared of ASD, ADHD risk in offspring

Prenatal paracetamol exposure cleared of ASD, ADHD risk in offspring

Nanoencapsulated sirolimus plus pegadricase helps patients with uncontrolled gout

Nanoencapsulated sirolimus plus pegadricase helps patients with uncontrolled gout

Elobixibat bests prucalopride for functional constipation in head-to-head trial

Elobixibat bests prucalopride for functional constipation in head-to-head trial

Medication nonadherence more common in young vs older adults with SLE

Medication nonadherence more common in young vs older adults with SLE

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

GLP-1 RAs confer cerebrovascular benefit in obstructive sleep apnoea

GLP-1 RAs confer cerebrovascular benefit in obstructive sleep apnoea